Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia (wAIHA), while the Japanese Ministry of Health, Labour and Welfare has simultaneously awarded Orphan Drug Designation (ODD) for the same indication. The novel oral reversible BTK inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, now advances toward first-in-class therapy for a rare anemia with no disease-targeting treatments currently available.
Forward‑Looking Statements This brief contains forward‑looking statements regarding rilzabrutinib regulatory approval timelines in wAIHA, commercial potential in rare autoimmune anemia, and Sanofi’s BTK platform expansion. Actual results may differ due to LUMINA 3 Phase 3 trial outcomes, competitive dynamics with FcRn inhibitors (efgartigimod) and complement blockers, and rare disease commercial execution challenges.-Fineline Info & Tech
By Fineline Cube